Oct. 2 at 1:15 PM
$SPRY $LLY $PFE $TEVA $AMGN
First and only worldwide alternative to EpiPen auto injectors! If you know any friends or family that suffer from anaphylaxis you know how big this is. This has just begun….
In the U.S., neffy is steadily expanding its prescriber base across allergy, primary care, and pediatrics – nearly doubling the breadth of prescribing over the last four months. Early direct-to-consumer campaigns have delivered meaningful lifts in awareness and engagement, which provide line of sight to a potentially attractive return on investment as spend scales. A consumer survey conducted in August 2025 showed more than 93% of patients were at least “very likely to consider” neffy if their healthcare provider recommended it, with 68% of those reporting they were “extremely likely to consider.” This investment from RA Capital and OMERS Life Sciences strengthens the company’s commercial strategy, underpinned by a body of real-world evidence supporting neffy's clinical equivalence to injection therapies and expanding prescriber confidence.
“Having seen my child hesitate to tell me she’s having a reaction because she fears the needle in an auto-injector, I consider neffy one of the most transformative innovations of my career,” said Peter Kolchinsky, Ph.D., Founder and Managing Partner at RA Capital and member of the ARS Pharma Board of Directors. “Before neffy, there was no needle-free choice. Now, she has successfully used neffy multiple times, and each time without hesitation. I believe everyone should know neffy exists and I’m proud to help fuel the launch of such an important product.”
